Abstract: Kanglaite injection is a new, broad-spectrum, antitumor diphase emulsion, which can be intravenously administered. In recent years, studies have demonstrated that the antitumor activities of Kanglaite include the redistribution of tumor cell cycle, apoptosis induction in tumor cells, tumor angiogenesis and tumor growth inhibition, and COX-2 expression downregulation. In addition, the treatment can prolong the repair time of radiation injuries. Moreover, Kanglaite injection improved the patients' immunity and their quality of life when combined with radiotherapy for the treatment of lung cancer, nasopharyngeal cancer, esophageal cancer, and metastatic tumors.